Modified oligonucleotides as therapeutic and diagnostic agents

https://doi.org/10.1016/0958-1669(95)80003-4Get rights and content

Abstract

Modified oligonucleotides and their analogs represent an exciting new class of agents with potential therapeutic and diagnostic applications. Among the most extensively investigated analogs are oligonucleoside phosphorothioates, some of which incorporate “hairpin’ structures at the 3′ end and ‘chimeras’ that bear two modified oligonucleotides, all potential therapeutic candidates. To further enhance their potential, bio-reversible analogs of oligonucleotides have been synthesized. Several isoteric analogs of phosphoric diester oligonucleotides with neutral achiral backbones, and other novel molecules, such as peptide nucleic acids and circular oligonucleotides, are also reported to form stable duplexes with complementary RNA/DNA and are currently under investigation. Additionally, oligonucleotides carrying a variety of fluorescent tags have been used as probes with potential for diagnostic applications.

References (58)

  • B Hyrup et al.

    Structure-activity studies of the binding of modified peptide nucleic acids (PNAS) to DNA

    J Am Chem Soc

    (1994)
  • RP Iyer et al.

    Stereospecific bio-reversibility of dinucleoside S-alkyl phosphorothiolates to dinucleoside phosphorothioates

    Bioorg Med Chem Lett

    (1994)
  • J Hovinen et al.

    Synthesis of 3'-O-(w-aminoalkyloxymethyl)thymidine 5'-triphosphates, terminators of DNA synthesis that enable 3'-labeling

    J Chem Soc Perkin Trans 1

    (1994)
  • A Balbi et al.

    Synthesis and complementary complex formation properties of oligonucleotides covalently linked to new stabilizing agents

    Tetrahedron

    (1994)
  • K Shinozuka et al.

    Bi-functional labeling of DNA with tris(2-aminoethyl)amine-derived novel fluorescent agent

    Bioorg Med Chem Lett

    (1993)
  • H Sands et al.

    Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate

    Mol Pharmacol

    (1994)
  • S Agrawal
    (1993)
  • S Agrawal
    (1993)
  • ST Crook et al.
    (1993)
  • PL Iverson et al.

    Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against Rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion

    Antisense Res Dev

    (1994)
  • PA Cossum et al.

    Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats

    J Pharmacol Exp Ther

    (1993)
  • J Temsamani et al.

    Pharmacokinetics, biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice

    Antisense Res Dev

    (1993)
  • CA Stein et al.

    Antisense oligonucleotides as therapeutic agents — is the bullet really magical?

    Science

    (1993)
  • KG Cornish et al.

    Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey

    Pharmacol Commun

    (1993)
  • WM Galbraith et al.

    Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in monkey

    Antisense Res Dev

    (1994)
  • E Bayever et al.

    Systematic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial

    Antisense Res Dev

    (1993)
  • N Lisziewicz et al.

    Antisense oligonucleotide phosphorothioate complementary to gag mRNA blocks HIV-1 replication in human peripheral blood cells

    Proc Natl Acad Sci USA

    (1994)
  • RF Azad et al.

    Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediately-early region

    Antimicrob Agents Chemother

    (1993)
  • Cited by (0)

    View full text